XOMA (NASDAQ:XOMA) Stock Passes Above 200-Day Moving Average of $25.91

Shares of XOMA Co. (NASDAQ:XOMA) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $25.91 and traded as high as $27.05. XOMA shares last traded at $26.00, with a volume of 40,936 shares.

Analysts Set New Price Targets

Several research firms have weighed in on XOMA. StockNews.com raised XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th. HC Wainwright restated a “buy” rating and set a $117.00 price target on shares of XOMA in a research report on Friday, September 20th.

XOMA Stock Performance

The company has a debt-to-equity ratio of 1.15, a quick ratio of 8.71 and a current ratio of 8.71. The business’s 50-day moving average is $27.38 and its 200-day moving average is $25.91. The company has a market capitalization of $304.20 million, a PE ratio of -6.63 and a beta of 0.93.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The company had revenue of $11.09 million during the quarter, compared to the consensus estimate of $8.37 million. XOMA had a negative return on equity of 24.50% and a negative net margin of 128.59%. On average, research analysts anticipate that XOMA Co. will post -1.42 earnings per share for the current year.

Institutional Investors Weigh In On XOMA

A number of institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets boosted its stake in XOMA by 55.6% in the 1st quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 1,266 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of XOMA during the first quarter valued at approximately $212,000. Rhumbline Advisers lifted its position in XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 1,334 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.